AR132085A1 - Compuestos y su uso en el tratamiento del cáncer - Google Patents

Compuestos y su uso en el tratamiento del cáncer

Info

Publication number
AR132085A1
AR132085A1 ARP240100579A ARP240100579A AR132085A1 AR 132085 A1 AR132085 A1 AR 132085A1 AR P240100579 A ARP240100579 A AR P240100579A AR P240100579 A ARP240100579 A AR P240100579A AR 132085 A1 AR132085 A1 AR 132085A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
atom
framework
atoms
Prior art date
Application number
ARP240100579A
Other languages
English (en)
Inventor
Peter Astles
James Scott
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR132085A1 publication Critical patent/AR132085A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: X¹ es CH o N; p es 0, 1 o 2; donde: cada R¹ es un sustituyente en cualquier átomo de C y se selecciona independientemente de F, Cl, alquilo C₁₋₃ y alcoxi C₁₋₃, en donde el alquilo C₁₋₃ y alcoxi C₁₋₃ pueden estar opcionalmente sustituidos de forma independiente por uno o más F; RN se selecciona de H y Me; n es 0, 1 o 2; m es 0 o 1; Q¹ es CH o N; cuando n y m son ambos distintos de 0, Q² es CH o N; cuando n y m son ambos 0, Q² es CH; cuando n es 0 o 1, Q³ es CH; cuando n es 2 y Q² es N, Q³ es CH; cuando n es 2 y Q² es CH, Q³ es CH u O; R²ᵃ y R²ᵇ son sustituyentes en átomos de C iguales o diferentes que no sean en Q¹ o Q², cada uno seleccionado independientemente de H, F y alquilo C₁₋₃, o R²ᵃ y R²ᵇ forman conjuntamente un grupo -(CH₂)ʳ- donde r es 1, 2 o 3; Q⁴ es un enlace individual o -NR⁴C(=O); R⁴ es H o Me; 0, 1 o 2 de Y¹, Y², Y³, Y⁴ e Y⁵ es / son N, y son de otro modo C; cada R³ es un sustituyente en cualquier átomo de C en Y¹, Y², Y³, Y⁴ e Y⁵, y se selecciona independientemente de F, Cl, CN, alquilo C₁₋₃ y alcoxi C₁₋₃, en donde el alquilo C₁₋₃ y alcoxi C₁₋₃ pueden estar opcionalmente sustituidos de forma independiente por uno o más F; q es 0, 1 o 2; en donde el Ligador está unido a cualquier átomo de C disponible en Y⁴ e Y⁵; el Ligador es un marco saturado o parcial o completamente no saturado que comprende átomos de C y H y al menos un heteroátomo, en donde dicho marco tiene puntos finales de unión ‘a’ y ‘b’ y una longitud de 5 a 26 átomos entre ‘a’ y ‘b’; en donde dicho marco puede incluir una o más cadenas y/o anillos rectos y/o ramificados y se sustituye opcionalmente en cualquier átomo o átomos de C disponibles por uno o más F; y W es una unidad de unión a cereblón de ubiquitina-ligasa E3.
ARP240100579A 2023-03-10 2024-03-08 Compuestos y su uso en el tratamiento del cáncer AR132085A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363489528P 2023-03-10 2023-03-10

Publications (1)

Publication Number Publication Date
AR132085A1 true AR132085A1 (es) 2025-05-21

Family

ID=90364229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100579A AR132085A1 (es) 2023-03-10 2024-03-08 Compuestos y su uso en el tratamiento del cáncer

Country Status (16)

Country Link
EP (1) EP4676922A1 (es)
JP (1) JP2026510359A (es)
KR (1) KR20250154418A (es)
CN (1) CN120835881A (es)
AR (1) AR132085A1 (es)
AU (1) AU2024235906A1 (es)
CL (1) CL2025002736A1 (es)
CO (1) CO2025013819A2 (es)
CR (1) CR20250426A (es)
DO (1) DOP2025000220A (es)
IL (1) IL323195A (es)
MX (1) MX2025010560A (es)
PE (1) PE20252537A1 (es)
TW (1) TW202502749A (es)
UY (1) UY40670A (es)
WO (1) WO2024189488A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250197411A1 (en) 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs
WO2026120044A1 (en) * 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
EP3795570B1 (en) * 2019-09-23 2022-02-23 Accutar Biotechnology Inc. Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
WO2021061644A1 (en) * 2019-09-23 2021-04-01 Accutar Biotechnology Inc. Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
WO2021231927A1 (en) * 2020-05-14 2021-11-18 The Regents Of The University Of Michigan Androgen receptor protein degraders with a tricyclic cereblon ligand

Also Published As

Publication number Publication date
KR20250154418A (ko) 2025-10-28
MX2025010560A (es) 2025-10-01
TW202502749A (zh) 2025-01-16
DOP2025000220A (es) 2025-10-31
UY40670A (es) 2024-09-13
CL2025002736A1 (es) 2026-01-02
IL323195A (en) 2025-11-01
AU2024235906A1 (en) 2025-10-30
EP4676922A1 (en) 2026-01-14
PE20252537A1 (es) 2025-10-27
CR20250426A (es) 2025-11-21
CO2025013819A2 (es) 2025-10-20
JP2026510359A (ja) 2026-04-02
WO2024189488A1 (en) 2024-09-19
CN120835881A (zh) 2025-10-24

Similar Documents

Publication Publication Date Title
AR112338A2 (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
AR119018A1 (es) Inhibidores de proteína quinasas dependientes de adn
AR071792A1 (es) Antagonistas nitrogenados del receptor de glucagon, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de la diabetes tipo ii y afecciones relacionadas.
AR088000A1 (es) Derivados de pirazolquinolinona, su preparacion y su uso terapeutico
AR104720A1 (es) Moduladores de ccr2
AR091962A1 (es) Compuesto antidiabeticos triciclicos
AR098912A1 (es) Inhibidores de syk
AR111850A1 (es) Trifluorometiloxadiazoles sustituidos para combatir hongos fitopatógenos
AR057626A1 (es) Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor
ES2662397T3 (es) Inhibidores de la quinasa reguladora de la señal de apoptosis
AR112392A1 (es) Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
CO6280476A2 (es) Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina
AR063800A1 (es) Derivados de acido nicotinico, composiciones farmaceuticas que las contienen y metodos de uso de los mismos
AR080467A1 (es) Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR107955A1 (es) Derivados de piridino- / pirimidino-piridina, con actividad herbicida
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR116474A1 (es) DERIVADOS DEL ÁCIDO 6,7-DIHIDRO-2H-BENZOFURO[2,3-a]QUINOLIZIN-3-CARBOXÍLICO COMO AGENTES ANTIVIRALES PARA EL TRATAMIENTO O PREVENCIÓN DE UNA INFECCIÓN POR HBV
AR098818A1 (es) Derivados de oxindol, preparación de los mismos y uso terapéutico de los mismos
AR122007A1 (es) Inhibidores de il4i1 y métodos de uso
PE20241934A1 (es) Inhibidores de raf quinasa y metodos de uso de los mismos
AR096161A1 (es) Derivados de triazina
AR128314A1 (es) Compuestos y su uso en el tratamiento del cáncer